Test Price
2,800 AED✅ Home Collection Available
GRIA3 Gene X‑Linked Intellectual Disability Type 94 Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity at Every Base Pair (ISO 9001:2015 Certified NGS).
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Daily 8 AM – 11 PM).
Clinical Guidance: Complimentary Telephonic Post‑Test Interpretation by a DHA‑Licensed Consultant Medical Genetics.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GRIA3 gene test is a targeted next‑generation sequencing (NGS) assay that detects pathogenic and likely pathogenic variants in the glutamate receptor 3 gene, which is causally implicated in X‑linked intellectual disability type 94. This focused analysis provides a definitive molecular diagnosis for unexplained neurodevelopmental delay, enabling precise clinical management, prognostic counselling, and recurrence risk assessment for families. The assay achieves a mean depth of coverage exceeding 200× across the entire GRIA3 coding region and conserved splice‑site junctions, ensuring high confidence in single‑nucleotide variant and small indel detection.
Compared with whole‑exome sequencing, this targeted approach delivers faster turnaround, higher coverage depth for the gene of interest, and a lower rate of variants of uncertain significance, making it the preferred first‑tier molecular test when the clinical phenotype strongly suggests GRIA3‑related disorder.
| Feature | Our GRIA3 NGS Test | Whole Exome Sequencing (Alternative) |
|---|---|---|
| Technology | Targeted NGS with high depth (>200×) | Exome capture, variable coverage |
| Clinical Scope | Focused on full GRIA3 gene coding region ± flanking introns | All protein‑coding genes |
| Detection Rate | 99.9% for SNVs/indels in targeted gene | 85–90% for coding variants; many VUS |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Price | 2,800 AED | 6,500+ AED (varies) |
| Post‑Test Support | Included genetic counselling; interpretation by DHA‑licensed specialist | External referral |
Physician Insight & Safety Protocols
“As Consultant Medical Genetics at DNA Labs UAE, I recognize that a genetic diagnosis can provide long‑sought answers for families affected by unexplained intellectual disability. This targeted NGS assay delivers high‑confidence results for GRIA3‑related X‑linked intellectual disability type 94, yet it must always be interpreted within the full clinical picture — including neurodevelopmental milestones, family pedigree, and neurological examination findings. A negative result does not exclude all genetic causes; we remain committed to guiding you through every step of the diagnostic journey.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory
Medication and Clinical Management Guidance
Do not discontinue or modify any prescribed medication, therapy, or intervention without consulting your treating physician. This genetic test is designed to inform diagnosis and long‑term management — it does not replace acute clinical care or existing treatment plans. Always integrate genetic findings with a comprehensive medical evaluation.
Exclusion Criteria & Emergency Red Flags
- Inability to provide a venous blood sample or refusal of the mandatory pre‑test genetic counselling session.
- Unavailability of legal guardian consent for minors, as required by UAE Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Acute coagulopathy or bleeding diathesis that precludes safe venipuncture.
- Emergency Red Flag: If the patient experiences sudden neurological deterioration — including new‑onset seizures, loss of consciousness, or stroke‑like symptoms — seek immediate emergency medical care. This elective genetic test is not intended for acute crisis diagnosis.
Patient FAQ & Clinical Guidance
1. What is the GRIA3 gene and why is it tested for intellectual disability?
The GRIA3 gene encodes the glutamate ionotropic receptor AMPA type subunit 3, a protein critical for synaptic transmission and neurodevelopment. Pathogenic variants in this gene disrupt glutamate signalling and are a known cause of X‑linked intellectual disability type 94. Testing identifies these variants to confirm a molecular diagnosis, inform prognosis, and guide family planning.
2. How accurate is the GRIA3 NGS test for diagnosing X‑linked intellectual disability?
The targeted NGS assay achieves 99.9% analytical sensitivity and specificity for single‑nucleotide variants and small insertions/deletions across the entire GRIA3 coding region and splice junctions. This performance meets and exceeds DHA molecular diagnostic standards, providing high confidence in both positive and negative results.
3. Is pre‑test genetic counselling mandatory in the UAE?
Yes. Under Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields and DHA genetic testing regulations, a certified genetic counselling session is mandatory to obtain informed consent, construct a detailed family pedigree, and ensure that the patient and family fully understand the implications of testing. Our Consultant Medical Genetics provides this counselling at no additional charge.
4. How long will it take to receive results and what support is provided after?
Results are available within 3 to 4 weeks from sample receipt. Reports are delivered through our secure online patient portal, followed by a telephone consultation with our DHA‑licensed Consultant Medical Genetics to explain the findings, discuss clinical implications, and outline next steps for management and family screening.
5. Can this test be performed on other family members for carrier testing?
Yes. Once a pathogenic variant is identified in the index patient, targeted variant testing can be offered to at‑risk female relatives for carrier status determination and to other family members for predictive testing. All cascade testing requires separate informed consent and genetic counselling, and is performed under the same DHA‑regulated framework.
UAE Regulatory & Data Privacy Adherence
All genetic testing services provided by DNA Labs UAE are fully compliant with the UAE legislative framework for health data protection and medical liability. Patient genetic data are processed, stored, and transmitted exclusively within regulated facilities in the UAE, ensuring strict confidentiality and security.
- Data Privacy: Governed by Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Aligns with Federal Decree‑Law No. 4 of 2016 on Medical Liability for all patient consent and clinical care standards.
- Quality Certification: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | GRIA3 Gene X‑Linked Intellectual Disability Type 94 Genetic Test (Targeted NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA) |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) with >200× mean depth, Sanger confirmation of all reportable variants |
| ICD‑10‑CM Code | F78 (Other intellectual disabilities) |
| LOINC Code | 92838-2 (GRIA3 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians